INTRODUCTION
Amyloidosis defi nes a group of diseases characterized by extracellular deposition of protein precursorsas insoluble fi brillar aggregates, able to induce both organ dysfunction and/or cellular death. Amyloid fibrils can be identifi ed in biopsy specimens both by their characteristic appearance on electron microscopy and by their ability to bind Congo red and thiofl avine-T. They are randomly organized and are approximately 8-10 nanometers in diameter. [1, 2] Despite a common beta fibrillar structure, the protein precursors and pathogenetic mechanisms of amyloid fi brils may vary according to the diff erent type of amyloidosis; amyloid light-chain (AL) (primary or immunoglobulin light chain associated), amyloid A (AA) (secondary or reactive to chronic infl ammation) and familial amyloidosis (AF) or heredofamilial. [3, 4] AA amyloidosis occurs in the se ing of longstanding infl ammation. Familial Mediterranean fever (FMF), chronic infections (such as tuberculosis), chronic rheumatologic diseases and inflammatory bowel disease are the most frequentetiologies.
according to criteria's described by Livneh et al. , [8] while other etiologies were reassessed by reviewing past medical records. The creatinine clearance was estimated by MDRD-4 formula. Stages of renal disease were classifi ed according to K/DOQI-NKF guidelines. Date of onset and type of dialysis and causes of death were recorded, if identifi ed. Deaths were recorded as unknown whenever the exact cause was not reported. SPSS 20 .0 so ware (SPSS Inc., Chicago, USA) was used for statistical analysis. Parametric data were presented as mean ± standard error. Student's t-test was used for parametric variables and Mann-Whitney U-test was used for nonparametric variables. Spearman and Pearson tests were used for correlation analysis. Yates correction Chi-square test and Fisher's exact test were used for comparison of qualitative data. Multivariate analyses were performed by logistic regression analysis. Survival was estimated by Kaplan-Meier and Log Rank (Mantel-Cox) test. P < 0.05 was considered to be signifi cant.
Statistical analysis

RESULTS
Data of 121 patients (34 females) were available to review. Mean age at diagnosis was 42.6 ± 14.4 (range: 17-74) years. Mean follow-up period was 38.2 ± 37.2 (1-167) months. Demographic features and laboratory fi ndings at diagnosis are given in Table 1 . FMF (37.1%) and tuberculosis (24.7%) were the most frequent causes, followed by unknown etiology (19.8%), chronic rheumatologic diseases (8.2%), chronic obstructive pulmonary diseases (6.6%) and others (3.3%). All FMF patients received 1-2 mg colchicine for an average of 8.7 ± 6.4 years prior to renal biopsy. Compared with FMF, patients who had underlying tuberculosis were older (P = 0.007) and had significantly lower levels of albumin (P = 0.005), higher levels of proteinuria (P = 0.007) and ferritin (P = 0.035) [ Table 1 ]. Amyloid deposition was mainly located in the glomerulus showing a mesangial nodular pa ern and extraglomerular vessels were involved in 65% of cases. Nephrotic syndrome was the presentation of 47 (38.5%) patients, whereas nonnephrotic proteinuria with and without renal failure was present in 41.5% and 20% of patients, respectively. Table 2 ]. Patients who needed dialysis were signifi cantly older, had higher serum urea, creatinine, phosphorus, intact parathormone, proteinuria and lower estimated glomerular fi ltration rate (eGFR), serum albumin, hemoglobin levels at presentation [ Table 3 ]. A multivariate logistic regression analysis showed that age, serum creatinine and albumin levels were predictors of ESRD [ Table 4 ]. Etiology was not a signifi cant predictor of requirement for dialysis. During the fi rst 3 months followup period 26 patients (21.4%) were started on dialysis and14 patients died (nine patients were receiving dialysis). Renal and patient survivals were not signifi cantly diff erent between FMF and tuberculosis groups, except for the fi rst 3 months where patients with tuberculosis signifi cantly more frequently required dialysis (8% vs. 23%, P = 0.004); and had a higher mortality rate (2.2% vs. 16.6%, P = 0.018).
Dialysis
Survival
Fi y patients (41.3%) died during follow-up period. Mean overall survival was 88.7 ± 7.8 months. Survival rates at 1, 2 and 5 years were 80.7%, 68.2% and 51.3%, respectively [ Table 5 ]. Older age, male gender, lower body mass index, eGFR, serum albumin and Ca levels, shorter time to dialysis, and higher levels of serum phosphorus, intact parathyroid hormone (iPTH), ferritin and protein uria were associated with lower odds of patient survival [ Table 5 ]. Overall mortality was not signifi cantly diff erent between patients with FMF and tuberculosis, except for greater mortality rate of tuberculosis patients within the fi rst 3 months of follow-up (P = 0.018).
Causes of death
Of 50 patients who died, 9 (18%) were due to chronic nutritional debility, which led to cachexia, malnutrition and infection, 26 (52%) were due to hypotension that led to complications of HD insuffi ciency such as uremia, hyperkalemia and hypervolemia, and 15 (30%) were due to unidentifi ed causes. The results are presented as mean ± SE. BMI = Body mass index; SE = Standard error; NS = Not signifi cant The results are presented as mean ± SD. FMF = Familial mediterranean fever; Tbc = Tuberculosis; CI = Confi dence interval; NS = Not signifi cant; SD = Standard deviation and tuberculosis. [5] [6] [7] In developed countries, rheumatic diseases comprise up to 75% of all causes of secondary amyloidosis; whereas FMF and tuberculosis were the most common underlying diseases both in our and in another large report from Turkey. [7] This diff erence is supported by a review of 64 patients with AA amyloidosis from the Mayo Clinic reporting that chronic rheumatologic disorders were responsible for 65% of cases, while 17% were due to chronic infections. [9] Renal involvement, typically manifested by nephrotic range proteinuria and renal failure, occurs in 80-90% of cases with amyloidosis and portends poor prognosis and high morbidity. [10] Long standing inflammation forms the basis of development of AA amyloidosis with a mean duration of latency was found 17 years in a UK series, though only a minority of these patients ends up with amyloidosis. [5] The reasons of this is not clear, but certain genetic isoforms of severe aplastic anemia (SAA) were found to increase the risk and severity of secondary amyloidosis. [11, 12] This field of research will provide practical methods to discriminate between high and low risk patients. The progressive nature of the disease may be predicted very early by the levels of serum AA protein in serum, where levels well above the reference range were shown be indicative of increased amyloid load and organ dysfunction. [13] As with more conventional methods, Gertz and Kyle analyzed 64 patients with AA The results are presented as mean ± SE. BMI = Body mass index; SE = Standard error; NS = Not signifi cant The results are presented as mean ± SD. SD = Standard deviation; CI = Confi dence interval
DISCUSSION
As a complication of chronic inflammatory diseases, chronic infections and FMF, AA amyloidosis is relatively a rare disease in the western world, whereas it is more common in Turkey due to the high prevalence of FMF amyloidosis and demonstrated that renal dysfunction (serum creatinine value of >2 mg/dL) at presentation was strongly associated with shorter survival. [9] Other studies also confi rmed that serum creatinine concentration is an important predictive factor for survival of patients with AA amyloidosis. [14] [15] [16] [17] In our study, patients with serum creatinine of >2 mg/dL and albumin <3.5 mg/dL had shorter both renal and overall survival. In addition, we also found that older age, male gender, higher levels of phosphorus, iPTH, albuminuria and lower levels of serum albumin, calcium, hemoglobin were associated with poor prognosis. This is supported by the fact that serum creatinine level, stage of renal disease, short time to dialysis, dialysis requirement and low serum albumin were found as predictors of mortality in logistic regression analysis.
Reports on survival vary depending on whether they are early or new, with older studies had a median survival ranging from 24 to 31 months. [9, 18, 19] Median survival of patients with creatinine levels of at least 1.69 mg/dL (150 μmol/L) was found 18 months in are port from 1989. [20] However, overall survival in our study was be er than older reports (mean: 88.7 ± 7.8 months). Furthermore, mean survival reached to nearly 10 years for patients who did not need dialysis.
Amyloidosis was associated with poor patient survival following dialysis and/or renal transplantation, reduced renal allogra survival and a signifi cant incidence of disease recurrence in the allogra . [21] Survival rates on dialysis were slightly lower in our patients when compared to 1, 2 and 6 years survival rates of 72%, 62% and 44% reported by Martinez, 1 and 5 year survival rates of 68% and 30% reported by Moroni et al., respectively. [22, 23] However, a study by Torregrosa showed that 1-year survival rate in dialysis was 42.7%, similar to our results. [24] Another report by Estevereveal even worse survival rates at 1 and 2 years, 30% and 5%, respectively. [25] However, in the analysis of studies by Moroni and Esteve the majority of patients had AA amyloidosis; they had also patients with primary (AL) amyloidosis included which could have altered the survival rates. The diff erences in survivals could also be due to socioeconomic factors, dialysis practices, extrarenal organ involvement, etc. Furthermore, underlying causes of AA amyloidosis may have an eff ect on survival, as our study showed that the diff erence in mortality between patients with FMF and tuberculosis was obvious in favor of FMF, although it did not reach a statistical signifi cance due to a low event rate. We were not able to assess the eff ect of normalizing infl ammation/high serum SAA, but both from a mechanistic standpoint and outcomes of a large series; one can understand that such an a empt should have a major role in prognosis. [5] None of the patients in our study received renal transplantation as a mean of renal replacement therapy. Although experience with renal transplantation is limited, studies suggest that patient and gra survivals are similar in amyloidosis and matched control groups with other disorders. [26, 27] In addition, pos ransplant recurrence of amyloidosis was also low (1 in 23 patients) with colchicine treatment. [26] These fi ndings should encourage clinicians to provide appropriate candidates with cadaveric or living donor transplantation, as morbidity and mortality with dialysis appear to be worse.
Similar to the features of our 31 patients with early mortality, Joss et al. reported that patients who commenced renal replacement therapy or died within 3 months of presentation were signifi cantly older, suff ered from more advanced renal disease, had more severe albuminuria and lower serum albumin levels. [28] In addition, we also found that these patients had higher phosphorus and iPTH, and lower calcium and hemoglobin levels.
Most common causes of mortality were renal failure (35%) and infections (8.5-46.6%) in previous series. [24, 29, 30] Either HD or PD can be used eff ectively for the treatment of ESRD due to amyloidosis, with the limiting factors being the degree of extra renal amyloid deposition, hypotension with HD, and peritonitis with continuous ambulatory peritoneal dialysis. [18] In the present study, most of the patients received HD treatment.
CONCLUSION REMARKS
Familial Mediterranean fever and tuberculosis are the most frequent underlying causes of AA amyloidosis. AA amyloidosis with renal involvement is progressive and carries a high risk of morbidity and mortality, particularly in those who had massive proteinuria, severe hypoalbuminemia and dialysis requirement at the outset. We suggest that careful evaluation of manifestations of amyloidosis may give the possibility of making earlier diagnosis, thereby prognosis could be improved. 
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